



American Society for
Dermatologic Surgery



360-Degree Injection Techniques and Strategy

AGENDA

Schedule

September 10, 2022: 7:30-8:30 am *Check-in & Breakfast* ♦ 8:30 am-6:00 pm *Sessions* ♦ 6:00-7:00 pm *Reception*

September 11, 2022: 7:45-8:45 am *Breakfast* ♦ 8:45 am-12:30 pm *Small Group/Hands-on Sessions*

InterContinental Chicago Magnificent Mile

505 Michigan Avenue ♦ Chicago, IL 60611

Directors: Vince Bertucci, MD, FRCPC ♦ Sue Ellen Cox, MD

Faculty: Kimberly Butterwick, MD ♦ Jordan Carqueville, MD ♦ Rebecca Fitzgerald, MD ♦ Deirdre Hooper, MD ♦ Omer Ibrahim, MD ♦ Jonathan Sykes, MD, FACS

Description

Full-circle, in-depth review of expert how-tos of cosmetic injections and facial anatomy! Designed for all experience levels and led by experts at the leading organization for cosmetic dermatologic surgeons, the course includes a series of high-yield lectures, panel discussions, live patient demonstrations featuring simultaneous anatomy demonstration on a prosected cadaveric cephalus specimen, real world case studies, hands-on training, plus more. Highlights include:

- ♦ Comprehensive facial analysis and assessment as applied to cosmetic injections
- ♦ Age-related structural changes to the face plus gender and ethnic considerations
- ♦ Essential injection facial anatomy, including small group in-depth anatomy deep dive
- ♦ Properties of and indications for biostimulators, hyaluronic acid fillers and neurotoxins
- ♦ Injection preparation pearls on neurotoxin dilution, hyper-blending, hyper-diluting and back-filling, and reconstituting poly-L-lactic acid in small-group format with hands-on training
- ♦ Strategies, tools and techniques for safer injection procedures with optimal outcomes
- ♦ Small group hands-on training with experts for injection techniques with needles and cannulas

Learning Objectives

Following this activity, participants should be able to:

- ♦ Recognize and identify facial anatomy as it relates to the use of cosmetic injections.
- ♦ Relate the principles of facial symmetry, aesthetics and aging to treatment strategies.
- ♦ Apply knowledge of facial anatomy, patient assessment, injectable agent properties and tools, and injection techniques to formulate comprehensive cosmetic treatment plans.

CME: 11.00 AMA PRA Category 1 Credits™

Please Note

- ♦ Schedule, agenda and faculty are subject to change.
- ♦ By attendance and participation in this course, you agree to allow ASDS to use photos taken by ASDS at this course for future promotions of ASDS programs.

Saturday, September 10, 2022

7:30 – 8:30 am	Check-in + Breakfast + Exhibits
8:30 – 9:00 am	Facial Analysis ♦ <i>Vince Bertucci, MD, FRCPC</i>
9:00 – 9:15 am	Gender and Ethnic Considerations ♦ <i>Omer Ibrahim, MD</i>
9:15 – 9:45 am	Facial Structural Changes with Aging ♦ <i>Rebecca Fitzgerald, MD</i>
9:45 – 10:30 am	Facial Injectable Anatomy ♦ <i>Jonathan Sykes, MD, FACS</i>
10:30 – 11:00 am	Break + Exhibits
11:00 – 11:30 am	Neurotoxins ♦ <i>Sue Ellen Cox, MD</i>
11:30 am – 12:10 pm	Hyaluronic Acid Fillers ♦ <i>Deirdre Hooper, MD and Jordan Carqueville, MD</i>
12:10 – 12:30 pm	Biostimulators on and off the Face ♦ <i>Kimberly Butterwick, MD</i>
12:30 – 1:30 pm	Lunch + Exhibits
1:30 – 3:30 pm	Patient Demonstrations with Simultaneous Anatomy Demonstration on Cadaver Cephalus
1:30 – 3:30 pm	Anatomy Demonstration throughout ♦ <i>Jonathan Sykes, MD, FACS</i>
1:30 – 2:00 pm	Upper Face ♦ <i>Omer Ibrahim, MD</i>
2:00 – 2:30 pm	Mid Face ♦ <i>Kimberly Butterwick, MD</i>
2:30 – 3:00 pm	Lower Face ♦ <i>Sue Ellen Cox, MD</i>
3:00 – 3:30 pm	Full Face ♦ <i>Vince Bertucci, MD, FRCPC</i>
3:30 – 4:00 pm	Break + Exhibits
4:00 – 5:15 pm	Real World Case Studies ♦ <i>All Faculty</i>
5:15 – 6:00 pm	Faculty Panel with Q&A ♦ <i>All Faculty</i>
6:00 – 7:00 pm	Networking Reception with Attendees, Faculty and Exhibitors

Saturday Conclusion

Course continues Sunday with Breakfast at 7:45 am and Session Start at 8:45 am

note: agenda and faculty subject to change

Sunday, September 11, 2022

7:45 – 8:45 am **Breakfast + Exhibits**

8:45 – 9:00 am **Move to Small Group Breakout Rotations**

9:00 – Noon **Small Group Breakout Rotations**

9:00 – 9:40 am Rotation 1
9:40 – 9:45 am Move to next group
9:45 – 10:25 am Rotation 2
10:25 – 10:30 am Move to next group
10:30 – 11:10 am Rotation 3
11:10 – 11:15 am Move to next group
11:15 am – Noon Rotation 4

Breakout Stations

1. **Patient Assessment** ♦ *Vince Bertucci, MD, FRCPC; Sue Ellen Cox, MD*
 2. **Anatomy Deep Dive** ♦ *Jonathan Sykes, MD, FACS*
 3. **Tools, Mixing and Prep** ♦ *Deirdre Hooper, MD; Omer Ibrahim, MD*
 4. **Injection Techniques with Needles and Cannulas** ♦ *Kimberly Butterwick, MD; Jordan Carqueville, MD; Rebecca Fitzgerald, MD*
-

12:00 – 12:30 pm **Faculty Panel with Q&A** ♦ *All Faculty*

Course Conclusion

note: agenda and faculty subject to change

CME INFORMATION

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The ASDS is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Category 1 Credit(s)[™]

The ASDS designates this live activity for a maximum of **11.00 AMA PRA Category 1 Credit(s)[™]**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Collection of Financial Relationships

ASDS collects information from all planners, faculty and others in control of educational content about all their financial relationships with *ineligible companies* (companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) within the prior 24 months. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of the relationship to the education.

Identifying and Mitigating Relevant Financial Relationships

ASDS reviews all disclosed financial relationships to determine relevance. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. All relevant financial relationships have been mitigated.

Disclosure of Financial Relationships

Financial relationships are disclosed to learners prior to the start of the educational activity via publication and/or disclosure slides and/or verbal disclosure. Disclosure provides learners with information so that they can make their own determination whether or not disclosed relationships influenced the content of an educational activity. Faculty and planner disclosure information is located at the end of this agenda/program document.

Unapproved Use Disclosure

Faculty are required to disclose to learners when off-label use of products or procedures are being discussed (not approved for the indications being discussed) or experimental and/or investigational (not FDA-approved). These disclosures are intended for continuing medical education, not to promote off-label use of products/procedures. If attendees have questions, they should contact the medical affairs department of the manufacturer for the current approved use information.

Disclaimer

Attendees understand that medical knowledge is constantly evolving, and that the views and techniques of faculty are their own and may reflect innovations and opinions not universally shared. The views and techniques of faculty are not necessarily those of ASDS but are presented to advance medical education and should be based on best available medical evidence. ASDS disclaims any and all liability arising out of information presented in this symposium, and also disclaims any and all liability for injury or other damage resulting in any way from attendance and participation in this educational activity.

Commercial Support Disclosure

The following commercial interest provided support in the form of an educational grant for this course at time of publication:

- AbbVie: in-kind gift injectable agents and monetary grant
- Evolus: in-kind gift injectable agents
- Galderma: in-kind gift injectable agents and monetary grant
- Revance: in-kind gift injectable agents and monetary grant
- Merz: in-kind gift injectable agents and monetary grant

Faculty Disclosure of Relationships with Ineligible Companies

Vince Bertucci, MD, FRCPC: Alastin: Advisory Board • Allergan: Advisory Board, Consultant, Primary Investigator, Speaker • Cutera: Speaker • Evolus: Advisory Board, Speaker • Galderma: Advisory Board, Consultant, Investigator, Speaker • Merz: Consultant, Speaker • Prolenium: Advisory Board, Consultant, Investigator, Speaker • Revance: Investigator.

Kimberly Butterwick, MD: Allergan: Advisory Board, Consultant • Merz: Advisory Board, Consultant • Galderma: Received Grant/Research Funding • Suneva: Advisory Board, Consultant, Speaker.

Jordan Carqueville, MD: No relevant financial relationships exist with ineligible companies.

Sue Ellen Cox, MD: Allergan: Advisory Board, Consultant, Primary Investigator • Evolus: Advisory Board, Consultant, Primary Investigator • Galderma: Advisory Board, Consultant, Primary Investigator • Merz: Advisory Board, Consultant • Revance: Advisory Board, Consultant, Primary Investigator, Stockholder • Chroma: Consultant, Primary Investigator • Zeltiq: Advisory Board, Consultant, Primary Investigator • Cearna Aesthetics: Consultant • Pulse Biosciences: Consultant, Received Free or Discounted Equipment • Solta Medical: Advisory Board, Consultant • Hugel: Advisory Board • Suneva: Advisory Board.

Rebecca Fitzgerald, MD: Revance Pharmaceuticals: Advisory Board, Stockholder.

Deirdre Hooper, MD: Allergan: Advisory Board, Consultant, Investigator, Speaker • Galderma: Advisory Board, Consultant, Investigator • Castle Biosciences: Advisory Board • Crown Laboratories: Advisory Board • Vichy Laboratories: Advisory Board • Dermtech: Advisory Board • Endo Aesthetics: Advisory Board, Investigator • Evolus: Advisory Board • Mayne Pharma: Consultant, Speaker • Revision: Advisory Board • RevHealth: Advisory Board, Speaker • RVL Pharmaceuticals: Speaker • Soopergoop: Ownership Interest • X-media: Speaker • Arcutis, Cara, Dermavant Services, Endo International, Galderma, Incyte, Taro, UCB: Investigator.

Omer Ibrahim, MD: Allergan: Advisory Board, Consultant • Galderma: Advisory Board, Consultant, Investigator, Primary Investigator • Revision: Advisory Board, Consultant.

Jonathan Sykes, MD: No relevant financial relationships exist with ineligible companies.

Planner Disclosure of Relationships with Ineligible Companies

Kachiu Lee, MD, MPH, ASDS Education Work Group Chair: No relevant financial relationships exist with ineligible companies.

Vince Bertucci, MD, FRCPC, Course Director: Alastin: Advisory Board • Allergan: Advisory Board, Consultant, Primary Investigator, Speaker • Cutera: Speaker • Evolus: Advisory Board, Speaker • Galderma: Advisory Board, Consultant, Investigator, Speaker • Merz: Consultant, Speaker • Prolenium: Advisory Board, Consultant, Investigator, Speaker • Revance: Investigator.

Sue Ellen Cox, MD, Course Director: Allergan: Advisory Board, Consultant, Primary Investigator • Evolus: Advisory Board, Consultant, Primary Investigator • Galderma: Advisory Board, Consultant, Primary Investigator • Merz: Advisory Board, Consultant • Revance: Advisory Board, Consultant, Primary Investigator, Stockholder • Chroma: Consultant, Primary Investigator • Zeltiq: Advisory Board, Consultant, Primary Investigator • Cearna Aesthetics: Consultant • Pulse Biosciences: Consultant, Received Free or Discounted Equipment • Solta Medical: Advisory Board, Consultant • Hugel: Advisory Board • Suneva: Advisory Board.